A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients

被引:40
|
作者
Zhong, Runbo [1 ]
Han, Baohui [1 ]
Zhong, Hua [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Dis, Shanghai 200030, Peoples R China
关键词
Chemoimmunotherapy; Dendritic cell; Cytokine-induced killer cell; Non-small cell lung cancer;
D O I
10.1007/s13277-013-1132-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dendritic cells (DC) play a crucial role in the induction of an effective antitumor immune response. Cytokine-induced killer (CIK) cells, a subset of T lymphocytes, have the capacity to eliminate cancer cells. This study was to evaluate the correlation between the frequency of DC/CIK immunotherapies following regular chemotherapy, the time-to-progression (TTP), and overall survival (OS) of advanced non-small lung cancer patients. Sixty patients with IIIB-IV non-small-cell lung carcinoma (NSCLC) were enrolled from August 2007 to December 2009 and were randomized into two groups. All 60 patients received four courses of navelbine-platinum (NP) chemotherapy. In one group, 30 patients were treated with adoptive autologous DC/CIK cell transfusion twice every 30 days. In the other group, the patients received immunotherapies more than twice every 30 days. The adverse effects, TTP, and OS were evaluated between the two groups. Median survival time of all 60 patients was 13.80 months. The 1-, 2-, and 3-year overall survival rates were 60.0, 21.7, and 15.0 %, respectively. The 1-, 2-, and 3-year overall survival rates of patients receiving more than two immunotherapies were 63.3, 30.0, and 23.3 %, and the rates of those receiving two immunotherapies were 56.7, 13.3, and 6.7 %, respectively. The difference between the two groups was statistically significant (P = 0.037). Compared with patients in the fewer immunotherapies group, TTP in the group receiving more immunotherapies significantly prolonged, with the median improving from 6.2 months (95 % CI, 5.35-9.24) to 7.3 months (95 % CI, 5.45-6.95; P = 0.034). The adverse effects of chemoimmunotherapy were tolerable. Advanced NSCLC patients can benefit from the combination of DC/CIK immunotherapies following conventional chemotherapy. More than two immunotherapies improved TTP and OS of those patients in this study.
引用
收藏
页码:987 / 994
页数:8
相关论文
共 50 条
  • [21] Chemotherapy in combination with cytokine-induced killer cell transfusion: An effective therapeutic option for patients with extensive stage small cell lung cancer
    Huang, Jianmin
    Kan, Quancheng
    Lan
    Zhao, Xuan
    Zhang, Zhen
    Yang, Shuangning
    Li, Hong
    Wang, Liping
    Xu, Li
    Cheng, Zhe
    Zhang, Yi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2017, 46 : 170 - 177
  • [22] Effect of cytokine-induced killer cells on immune function in patients with lung cancer
    Pan, Yanyan
    Wu, Yuanyuan
    Ji, Jun
    Cai, Hongjiao
    Wang, Heshuang
    Jiang, Yifan
    Sang, Limin
    Yang, Jin
    Gao, Yanyan
    Liu, Ying
    Yin, Liangwei
    Zhang, Li
    ONCOLOGY LETTERS, 2016, 11 (04) : 2827 - 2834
  • [23] Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
    Ulahannan, Susanna V.
    Brahmer, Julie R.
    CANCER INVESTIGATION, 2011, 29 (04) : 325 - 337
  • [24] CETUXIMAB IN COMBINATION WITH CHEMOTHERAPY IN CHINESE PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Si, X-Y
    Zhang, Li.
    RESPIROLOGY, 2011, 16 : 133 - 133
  • [25] A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines
    Li, Yutao
    Sharma, Amit
    Wu, Xiaolong
    Weiher, Hans
    Skowasch, Dirk
    Essler, Markus
    Schmidt-Wolf, Ingo G. H.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Breast cancer treatment by transplantations of dendritic cells and cytokine-induced killer cells: An update on clinical trials
    Hieu Trong Ngo
    Phuc Van Pham
    BIOMEDICAL RESEARCH AND THERAPY, 2021, 8 (11): : 4700 - 4717
  • [27] Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study
    Li, Runmei
    Wang, Changli
    Liu, Liang
    Du, Chunjuan
    Cao, Shui
    Yu, Jinpu
    Wang, Shizhen Emily
    Hao, Xishan
    Ren, Xiubao
    Li, Hui
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (11) : 2125 - 2133
  • [28] Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study
    Runmei Li
    Changli Wang
    Liang Liu
    Chunjuan Du
    Shui Cao
    Jinpu Yu
    Shizhen Emily Wang
    Xishan Hao
    Xiubao Ren
    Hui Li
    Cancer Immunology, Immunotherapy, 2012, 61 : 2125 - 2133
  • [29] THE COMBINATION CHEMOTHERAPY OF GEMCITABINE, CARBOPLATIN AND BEVACIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Kim, Bong Seog
    Ahn, Young Mi
    Lee, Moon Hyung
    Suh, Kang Heum
    Nam, Seung-Hyun
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1158 - S1158
  • [30] Combination of chemotherapy and radiotherapy for locally advanced non-small cell lung cancer
    Fournel, P.
    REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : S94 - S100